Myohanen TT, Hannula MJ, Van Elzen R, Gerard M, Van der Veken P, Garcia-Horsman JA, Baekelandt V, Mannisto PT, Lambeir AM (2012) <br />A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease<br /><i>British Journal of Pharmacology</i> <b>166</b>: 1097<br /><br />Van der Veken P, Fulop V, Rea D, Gerard M, Van Elzen R, Joossens J, Cheng JD, Baekelandt V, De Meester I, Lambeir AM, Augustyns K (2012) <br />P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy<br /><i>Journal of Medicinal Chemistry</i> <b>55</b>: 9856<br /><br />Brandt I, Gerard M, Sergeant K, Devreese B, Baekelandt V, Augustyns K, Scharpe S, Engelborghs Y, Lambeir AM (2008) <br />Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein<br /><i>Peptides</i> <b>29</b>: 1472<br /><br />